1. Name Of The Medicinal Product
Lopresor Tablets 100mg
2. Qualitative And Quantitative Composition
Each tablet contains 100mg metoprolol tartrate BP
3. Pharmaceutical Form
Film coated tablet
4. Clinical Particulars
4.1 Therapeutic Indications
Hypertension and angina pectoris, cardiac arrhythmias, especially supraventricular tachyarrhythmias. Adjunct to treatment of thyrotoxicosis. Early intervention ith Lopresor in myocardial infarction reduces infarct size and the incidence of ventricular fibrillation. Pain relief may also decrease the need for opiate analgesics. Lopresor has been shown to reduce mortality when administered to patients with acute myocardial infarction. Prophylaxis of migraine.
4.2 Posology And Method Of Administration
Lopresor tablets should be administered orally and swallowed unchewed. The dose must always be adjusted to the individual requirements of the patient but should not exceed 400mg/day. The following are guidelines:
Adults
Hypertension: initially a dose of 100mg per day should be prescribed either as single or divided doses. Depending upon the response the dosage may be increased by 100mg per day at weekly intervals to 200mg daily given in single or divided doses. Over the dosage range most patients may be expected to respond rapidly and satisfactorily. A further reduction in blood pressure may be achieved if Lopresor is used in conjunction with an antihypertensive diuretic or other hypotensive agent.
Lopresor may be administered with benefit both to previously untreated patients with hypertension and to those in whom the response to previous therapy is inadequate. In the latter type of patient the previous therapy may be continued and Lopresor added into the regime with adjustment of the previous therapy if necessary.
Angina Pectoris: 50-100mg twice or three times daily
In general a significant improvement in exercise tolerance and reduction of anginal attacks may be expected with a dose of 50-100mg twice daily.
Cardiac Arrhythmias: A dosage of 50mg two or three times daily is usually sufficient. If necessary the dose can be increased up to 300mg per day administered in divided doses.
Hyperthyroidism: 50mg four times daily. The dosage should be progressively reduced as euthyroid state is slowly achieved.
Myocardial Infarction:
Early intervention: 50mg every 6 hours for 48 hours, preferably within 12 hours of the onset of chest pain.
Maintenance: the usual maintenance dose is 200mg daily given in divided doses. The treatment should be continued for at least 3 months.
Prophylaxis of Migraine: 100-200mg daily, given in divided doses (morning and evening).
Elderly
There is no evidence to suggest that dosage requirements are different in otherwise healthy elderly patients. However, caution is indicated in elderly patients as an excessively pronounced decrease in blood pressure or pulse rate may cause the blood supply to vital organs to fall to inadequate levels.
In patients with significant hepatic dysfunction the lower dosage recommendations will be more appropriate.
Children
Not recommended
4.3 Contraindications
Known hypersensitivity to metoprolol and related derivatives or to any of the excipients, severe asthma or history of severe bronchospasm, atrioventricular block of second or third degree, uncontrolled heart failure, clinically relevant sinus bradycardia, sick-sinus syndrome, severe peripheral arterial disease, cardiogenic shock, hypotension, untreated phaeochromocytoma, metabolic acidosis.
Metoprolol is also contraindicated when myocardial infarction is complicated by significant bradycardia, first degree heart block, systolic hypotension (less than 100mmHg) and/or severe heart failure.
4.4 Special Warnings And Precautions For Use
A warning stating “Do not take this medicine if you have a history of wheezing or asthma” will appear on the label.
Although cardioselective beta-blockers, including Lopresor, may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers these should be avoided in patients with reversible obstructive airway disease unless there are compelling clinical reasons for their use. Therapy with a beta2- stimulant may become necessary or current therapy require adjustment.
Metoprolol may aggravate bradycardia and symptoms of peripheral arterial circulatory disorders. If the patient develops increasing bradycardia, (heart rate less than 50 to 55 beats/min) Lopresor should be given in lower doses or gradually withdrawn.
In addition, anaphylactic reactions precipitated by other agents may be particularly severe in patients taking β-blockers, and may be resistant to normal doses of adrenaline. Whenever possible, β-blockers, including Lopresor, should be avoided for patients who are at increased risk of anaphylaxis
Abrupt cessation of therapy with a beta-blocker should be avoided, especially in patients with ischaemic heart disease. When possible, Lopresor should be withdrawn gradually over a period of 10 days, the doses diminishing to 25mg for the last 6 days. During its withdrawal, the patient should be kept under close surveillance and replacement therapy should be initiated where required.
Beta-blockers, including Lopresor, should not be used in patients with untreated congestive heart failure ( see “Contraindications”). This condition should first be stabilised. Additional therapy should also be considered for patients with a history of heart failure or patients who are known to have a poor cardiac reserve, e.g. diuretics and/or digitalisation.
Because of their negative effect on atrioventricular conduction, beta-blockers, including Lopresor, should be given only with caution to patients with first degree atrioventricular block (see “Contraindications”)
Beta-blockers mask some of the clinical signs of thyrotoxicosis. Therefore, Lopresor should be administered with caution to patients having, or suspected of developing, thyrotoxicosis, and both thyroid and cardiac function should be monitored closely
Lopresor should be used with caution in patients with diabetes mellitus, especially those who are receiving insulin or oral hypoglycaemic agents (see “Interactions with other medicaments and other forms of interaction”). In labile and insulin-dependent diabetes it may be necessary to adjust the hypoglycaemic therapy. Lopresor may mask some of the symptoms of hypoglycaemia by inhibition of sympathetic nerve functions and patients should be warned accordingly.
In patients with a treated phaeochromocytoma, an alpha-blocker should be given concomitantly.
In patients with significant hepatic dysfunction it may be necessary to adjust the dosage because metoprolol undergoes biotransformation in the liver.
The administration of adrenaline to patients undergoing beta-blockade can result in an increase in blood pressure and bradycardia although this is less likely to occur with beta1-selective drugs.
Lopresor therapy should be brought to the attention of the anaesthetist prior to general anaesthesia. The benefits of continuing a treatment with a beta-blocker, including Lopresor, should be balanced against the risk of withdrawing it in each patient. When it has been decided to interrupt a beta-blockade in preparation for surgery, therapy should be discontinued for at least 24 hours. Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. However, the risk of hypertension may be increased. If treatment is continued, caution should be observed with the use of certain anaesthetic drugs. In a patient under beta-blockade, the anaesthetic selected should be one exhibiting as little negative inotropic activity as possible (halothane/nitrous oxide). The patient may be protected against vagal reactions by intravenous administration of atropine.
Beta-blockers may increase the number and duration of angina attacks in patients with Prinzmetal's angina (variant angina pectoris). However, relatively selective beta1-receptor blockers, such as Lopresor, can be used in such patients, but only with the utmost care
Patients with anamnestically known psoriasis should take beta-blockers only after careful consideration.
The full oculomucocutaneous syndrome, as described elsewhere with practolol, has not been reported with Lopresor. However, part of this syndrome (dry eyes either alone or, occasionally, with skin rashes) has occurred. In most cases the symptoms cleared when Lopresor treatment was withdrawn. Patients should be observed carefully for potential ocular effects. If such effects occur, discontinuation of Lopresor should be considered. (see advice about discontinuation above).
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
The effects of metoprolol and other antihypertensive drugs on blood pressure are usually additive, and care should be taken to avoid hypotension. However, combinations of antihypertensive drugs may often be used with benefit to improve control of hypertension.
As beta-blockers may affect the peripheral circulation, care should be exercised when drugs with similar activity, e.g. ergotamine are given concurrently.
Care should also be exercised when beta-blockers are given in combination with sympathetic ganglion blocking agents, other beta-blockers (also in the form of eye drops) or MAO inhibitors.
Prazosin
The acute postural hypotension that can follow the first dose of prazosin may be increased in patients already taking a beta-blocker
Clonidine
If combination treatment with clonidine is to be discontinued metoprolol should be withdrawn several days before clonidine.This is because the hypertension that can follow withdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment
Calcium channel blockers
Calcium channel blockers such as verapamil and diltiazem may potentiate the depressant effects of beta-blockers on blood pressure, heart rate, cardiac contractility and atrioventricular conduction. A calcium channel blocker of the verapamil (phenylalkylamine) type should not be given intravenously to patients receiving Lopresor because there is a risk of cardiac arrest in this situation. Patients taking an oral calcium channel blocker of the verapamil type in combination with Lopresor should be closely monitored
CYP2D6 inhibitors
Potent inhibitors of this enzyme may increase the plasma concentration of metoprolol (see section 5.2. Pharmacokinetic properties). Caution should therefore be exercised when co-administering potent CYP2D6 inhibitors with metoprolol. Known clinically significant potent inhibitors of CYP2D6 are antidepressants such as fluoxetine, paroxetine or bupropion, antipsychotics such as thioridazine, antiarrhythmics such as propafenone, antiretrovirals such as ritonavir, antihistamines such as diphenhydramine, antimalarials such as hydroxychloroquine or quinidine, antifungals such as terbinafine and medications for stomach ulcers such as cimetidine.
Class I anti-arrhythmic drugs and amiodarone
Amiodarone, propafenone, and other class I anti-arrhythmic agents such as quinidine and disopyramide may potentiate the effects of beta-blockers on heart rate and atrioventricular conduction
Nitroglycerin
Nitroglycerin may enhance the hypotensive effect of Lopresor.
Digitalis glycosides
Concurrent use of digitalis glycosides may result in excessive bradycardia and/or increase in atrioventricular conduction time.
Sympathomimetics
Metoprolol will antagonise the beta1 effects of sympathomimetic agents but should have little influence on the bronchodilator effects of beta2-agonists at normal therapeutic doses.
Insulin and oral hypoglycaemic drugs
In diabetic patients who use insulin, beta-blocker treatment may be associated with increased or prolonged hypoglycaemia. Beta-blockers may also antagonise the hypoglycaemic effects of sulfonylureas. The risk of either effect is less with a beta1-selective drug such as Lopresor than with a non-selective beta-blocker. However, diabetic patients receiving Lopresor should be monitored to ensure that diabetes control is maintained (see also “Special warnings and special precautions for use”).
Non-steroidal anti-inflammatory drugs
Concurrent treatment with non-steroidal anti-inflammatory drugs such as indomethacin may decrease the antihypertensive effect of metoprolol.
Lignocaine
Metoprolol may impair the elimination of lignocaine.
General anaesthetics
Some inhalation anaesthetics may enhance the cardiodepressant effect of beta-blockers (see “Special warnings and special precautions for use”)
Hepatic enzyme inducers/inhibitors
Enzyme inducing agents (e.g. rifampicin) may reduce plasma concentrations of metoprolol, whereas enzyme inhibitors (e.g. cimetidine) may increase plasma concentrations.
Alcohol
During concomitant ingestion of alcohol and metoprolol the concentration of blood alcohol may reach higher levels and may decrease more slowly.
4.6 Pregnancy And Lactation
Beta-blockers reduce placental perfusion which may result in intrauterine foetal death, immature and premature deliveries . Lopresor should not be used in pregnancy or lactation unless it is considered that the benefit outweighs the possible risk to the foetus/infant.
Metoprolol has, however, been used in pregnancy associated hypertension under close supervision after 20 weeks gestation. Although the drug crosses the placental barrier and is present in cord blood no evidence of foetal abnormalities have been reported. Animal experiments have shown neither teratogenic potential nor other adverse events on the embryo and/or foetus relevant to the safety assessment of the product.
The amount of metoprolol ingested via breast milk seems to be negligible with regard to its beta-blocking effects if the mother is treated in doses within the therapeutic range.
If Lopresor is used during pregnancy and lactation special attention should be paid to the foetus, neonate and breast-fed infant for undesirable effects of the drug's beta-blocking action (e.g. bradycardia, hypoglycaemia). The lowest possible dose should be used, and treatment should be discontinued at least 2 to 3 days before delivery to avoid increased uterine contractility and effects of beta-blockade in the newborn baby.
4.7 Effects On Ability To Drive And Use Machines
As with all beta-blockers, metoprolol may affect patients' ability to drive and operate machinery. Patients should be warned accordingly.
4.8 Undesirable Effects
Frequency estimates: very common
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Post Marketing Experience
The following adverse reactions have been reported during post-approval use of Lopresor: confusional state, an increase in blood triglycerides and a decrease in high density lipoprotein (HDL). Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.
4.9 Overdose
Signs and symptoms
In more severe cases an overdosage of metoprolol may lead to severe hypotension, sinus bradycardia, atrioventricular block, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, impairment of consciousness, coma, convulsions, nausea, vomiting, cyanosis, hypoglycaemia and occasionally hyperkalaemia.
The first manifestations of overdosage appear 20 minutes to 2 hours after ingestion of Lopresor. The effects of massive overdose may persist for several days, despite declining plasma concentrations
Treatment
Patients should be admitted to hospital and, generally, should be managed in an intensive care setting, with continuous monitoring of cardiac function, blood gases, and blood biochemistry. Emergency supportive measures such as artificial ventilation or cardiac pacing should be instituted if appropriate. Even apparently well patients who have taken a small overdose should be closely observed for signs of poisoning for at least 4 hours.
In the event of a potentially life-threatening oral overdose, use induction of vomiting or gastric lavage (if within 4 hours after ingestion of Lopresor) and/or activated charcoal to remove the drug from the gastrointestinal tract. Metoprolol can not be effectively removed by haemodialysis.
Atropine may be given intravenously to control significant bradycardia. Intravenous beta-agonists such as prenalterol or isoprenaline should be used to treat bradycardia and hypotension; very high doses may be needed to overcome the beta-blockade. Dopamine, dobutamine or noradrenaline may be given to maintain blood pressure. Glucagon has positive inotropic and chronotropic effects on the heart that are independent of beta-adrenergic receptors, and has proved effective in the treatment of resistant hypotension and heart failure associated with beta-blocker overdose.
Diazepam is the drug of choice for controlling seizures. A beta2-agonist or aminophylline can be used to reverse bronchospasm; patients should be monitored for evidence of cardiac arrhythmias during and after administration of the bronchodilator.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group
Lopresor is a cardioselective beta-adrenergic blocking agent.
Mechanism of action
It has a relatively greater blocking effect on beta1-receptors (i.e. those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta2-receptors which are chiefly involved in broncho and vasodilation. It has no membrane-stabilising effect nor partial agonist (intrinsic sympathomimetic) activity.
The stimulant effect of catecholamines on the heart is reduced or inhibited by metoprolol. This leads to a decrease in heart rate, cardiac contractility and cardiac output.
5.2 Pharmacokinetic Properties
Absorption
Metoprolol is well absorbed after oral administration, peak plasma concentrations occurring 1.5 - 2 hours after dosing. The bioavailability of a single dose is approximately 50%, increasing to approximately 70% during repeated administration. The bioavailability also increases if metoprolol is given with food.
Distribution and Biotransformation
Approximately 10% of metoprolol in plasma is protein bound. Metoprolol crosses the placenta, and is found in breast milk (see “Pregnancy and lactation”).
Metoprolol is extensively metabolised by enzymes of the cytochrome P450 system in the liver. The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolisers (PM) phenotype. Approximately 7% of Caucasians and less than 1% Orientals are PMs.
CYP2D6 poor metabolisers exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolisers with normal CYP2D6 activity. None of the metabolites of metoprolol contribute significantly to its beta-blocking effect.
Elimination
Elimination is mainly by hepatic metabolism and the average elimination half-life is 3.5 hours (range 1 to 9 hours). Rates of metabolism vary between individuals, with poor metabolisers (approximately 10%) showing higher plasma concentrations and slower elimination than extensive metabolisers. Within individuals, however, plasma concentrations are stable and reproducible.
Characteristics in Patients
Because of variation in rates of metabolism, the dose of metoprolol should always be adjusted to the individual requirements of the patient. As the therapeutic response, adverse effects and relative cardioselectivity are related to plasma concentration, poor metabolisers may require lower than normal doses. Dosage adjustment is not routinely required in the elderly or in patients with renal failure, but dosage may need to be reduced in patients with significant hepatic dysfunction when metoprolol elimination may be impaired.
5.3 Preclinical Safety Data
There are no further data of relevance to the prescriber.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Avicel PH101, povidone, Aerosil 200, sodium starch glycollate, magnesium stearate, hydroxypropylmethylcellulose, polysorbate 80, purified special talc, dispersed blue (E132), titanium dioxide (E171).
6.2 Incompatibilities
None known.
6.3 Shelf Life
60 months.
6.4 Special Precautions For Storage
Protect from moisture.
6.5 Nature And Contents Of Container
56 tablets in an Al/PVC(PVdC) blister pack.
6.6 Special Precautions For Disposal And Other Handling
Not applicable.
7. Marketing Authorisation Holder
Recordati Pharmaceuticals Limited
Isis House
43 Station Road
Henley-on-Thames
Oxfordshire
RG9 1AT
UK
8. Marketing Authorisation Number(S)
PL 25046/0010
9. Date Of First Authorisation/Renewal Of The Authorisation
06 June 1997 / 22 October 2003
10. Date Of Revision Of The Text
06/10/2010
No comments:
Post a Comment